India bans use of PET in pharmaceutical industry
The Ministry stated that the use of PET and plastic packaging for pharmaceutical products is hazardous to humans’ health due to the presence of endocrine disruptors. It was also decided that India had different environmental conditions than some of the developed countries which continue to use similar packaging as temperatures in the country reach as high as 45-50 degrees centigrade, creating greater risks of degradation. The pharmacy companies were given six months to switch to glass packaging in spite of the fact that it is much more expensive. Glass packaging provides healthier conditions and preserves the efficacy of liquid formulations, according to government officials.
The value of the PET market in the country was estimated to be around $1.6 billion, and before the ban, it was expected to reach $2.15 billion by 2016, according to industry analysts.
More free plastics newsPlastic resin (PP, LDPE, LLDPE ,HDPE, PVC, GPS; HIPS, PET, ABS) prices, polymer market trends, and more...
- Further price cuts in Vietnam’s PP market fail to revive demand
- Asian PS, ABS markets remain weak on rising trade tensions
- Spot styrene sharply down in Europe and Asia
- Expectations soften for PP raffia, fibre yet to follow in Turkey
- Will PE supplies from China flock to SEA?
- LDPE, LLDPE highest since Q3 2018; HDPE at 6-month high in Europe
- Intensifying trade war adds to bearishness in China’s local PP, PE markets
- PET prices hit multi-month lows in Asia and Europe
- Rising momentum fizzles out in European PS, ABS markets
- European PVC offers to Turkey shrug off higher costs